iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $591.84M | $492.68M | $410.92M | $322.82M | $265.17M | $214.55M | $147.28M | $99.13M |
| Cost of Revenue | $184.31M | $160.88M | $129.29M | $109.26M | $70.28M | $52.48M | $38.80M | $28.20M |
| Gross Profit | $407.53M | $331.81M | $281.63M | $213.57M | $194.89M | $162.07M | $108.48M | $70.93M |
| Gross Margin | 68.86% | 67.35% | 68.54% | 66.16% | 73.50% | 75.54% | 73.66% | 71.55% |
| Operating Expenses | $523.04M | $456.97M | $395.42M | $313.51M | $238.56M | $216.82M | $154.17M | $98.52M |
| Operating Income | $-115.50M | $-125.16M | $-113.78M | $-99.94M | $-43.67M | $-54.76M | $-45.69M | $-27.59M |
| Operating Margin | -19.52% | -25.40% | -27.69% | -30.96% | -16.47% | -25.52% | -31.02% | -27.83% |
| Net Income | $-113.29M | $-123.41M | $-116.16M | $-101.36M | $-43.83M | $-54.57M | $-50.38M | $-29.74M |
| Net Margin | -19.14% | -25.05% | -28.27% | -31.40% | -16.53% | -25.43% | -34.21% | -30.00% |
| EPS (Basic) | $-3.63 | $-4.04 | $-3.88 | $-3.46 | $-1.58 | $-2.16 | $-2.02 | $-1.30 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |